Ranibizumab

Indication

Macular Oedema - retinal vein occlusion (NICE TA283)

NICE TA283 - Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Red

Brand:

Lucentis®

Nice TA:

283

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Eye

Background

CCGs should only fund treatment obtained through the patient access scheme

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Pending	Red	Red	Pending	Red	Red	Red	Red

What do the colours mean?

Last Updated: 16 - Oct - 2019